85岁以上4人中就有一个罹患阿尔茨海默病？血检大规模推广仍存争议

Group 1 - The core finding of recent research indicates that approximately 10% of individuals aged 70 and older exhibit signs of dementia and Alzheimer's disease pathology, with this figure rising to 25% in those aged 85 and above [1] - The study involved over 10,000 participants and highlighted that 10% of the 70+ age group showed cognitive impairment and elevated pTau217 levels, while another 10% had mild cognitive impairment with high pTau217 levels [1] - The blood test for Alzheimer's disease diagnosis is gaining traction globally, but there is ongoing debate about its sufficiency as a standalone early screening tool [1][2] Group 2 - Approximately 19% of dementia patients have low pTau217 levels in their blood, suggesting that their cognitive issues may stem from other causes [2] - Alzheimer's disease accounts for 60% to 80% of all dementia cases globally, as reported by the Alzheimer's Association [2] - Blood-based biomarkers for Alzheimer's disease are being developed to enhance the understanding of brain health and could serve as cost-effective tools for early screening and ongoing monitoring, particularly in older populations [2][3] Group 3 - According to the latest guidelines from the Alzheimer's Association, blood biomarkers have two main clinical uses: as efficient triage tools to determine the need for further diagnostic imaging or cerebrospinal fluid testing, and for direct pathological identification of amyloid proteins [3] - It is emphasized that results interpretation must consider the patient's age, clinical profile (such as cognitive scores), and various risk factors including comorbidities [3]